As of 2026-09-12, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -2.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,164.23 mil USD. RXRX's TTM EBITDA according to its financial statements is -466.68 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.2x - 16.3x | 16.0x |
| Forward P/E multiples | 17.2x - 19.7x | 18.5x |
| Fair Price | (14.16) - (13.32) | (14.17) |
| Upside | -542.6% - -516.2% | -542.7% |
| Date | EV/EBITDA |
| 2026-09-11 | -2.49 |
| 2026-09-10 | -2.45 |
| 2026-09-09 | -2.51 |
| 2026-09-08 | -2.77 |
| 2026-09-04 | -2.98 |
| 2026-09-03 | -2.77 |
| 2026-09-02 | -2.70 |
| 2026-09-01 | -2.64 |
| 2026-08-31 | -2.72 |
| 2026-08-28 | -2.65 |
| 2026-08-27 | -2.77 |
| 2026-08-26 | -2.82 |
| 2026-08-25 | -2.90 |
| 2026-08-24 | -2.55 |
| 2026-08-21 | -2.84 |
| 2026-08-20 | -2.65 |
| 2026-08-19 | -2.84 |
| 2026-08-18 | -2.37 |
| 2026-08-17 | -2.39 |
| 2026-08-14 | -2.45 |
| 2026-08-13 | -2.62 |
| 2026-08-12 | -2.60 |
| 2026-08-11 | -2.67 |
| 2026-08-10 | -2.60 |
| 2026-08-07 | -2.52 |
| 2026-08-06 | -2.47 |
| 2026-08-05 | -2.46 |
| 2026-08-04 | -2.62 |
| 2026-08-03 | -2.47 |
| 2026-07-31 | -2.27 |
| 2026-07-30 | -2.31 |
| 2026-07-29 | -2.23 |
| 2026-07-28 | -2.32 |
| 2026-07-27 | -2.28 |
| 2026-07-24 | -2.22 |
| 2026-07-23 | -2.28 |
| 2026-07-22 | -2.24 |
| 2026-07-21 | -2.36 |
| 2026-07-20 | -2.14 |
| 2026-07-17 | -2.21 |
| 2026-07-16 | -2.29 |
| 2026-07-15 | -2.62 |
| 2026-07-14 | -2.65 |
| 2026-07-13 | -2.61 |
| 2026-07-10 | -2.90 |
| 2026-07-09 | -3.13 |
| 2026-07-08 | -3.09 |
| 2026-07-07 | -3.22 |
| 2026-07-06 | -3.36 |
| 2026-07-02 | -3.18 |